Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model
about
Role of isavuconazole in the treatment of invasive fungal infectionsIsavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsIsavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendationsClinical implications of globally emerging azole resistance in Aspergillus fumigatus.Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary AspergillosisPharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis.Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment.Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.Global Aspects of Triazole Resistance in Aspergillus fumigatus with Focus on Latin American Countries.Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.
P2860
Q26740837-633815C7-38B1-4B69-9972-8DF2D48AF8B3Q26744049-1D932085-0C62-417F-8BAF-C75AFF93344DQ28067726-D80D2DDB-581A-4853-B2C2-2F28B91CE3FCQ30239051-00E8BF7B-8CAE-4F69-ACD0-70FE8B03A64AQ33689767-1DE56672-C3E5-4ECD-A5BA-B2AD2D93CAD7Q36439102-7FE3DBA4-8E5A-421A-9A61-2D044712CDDEQ36887855-D9321085-1DA4-40C8-8D7C-D9457FF4E300Q36977398-06548455-554C-4506-8D26-F172382ABF4FQ37119937-D2BB3E4B-A6E4-4649-89FE-5E9D8B7CDBD9Q37203893-731B2F43-0692-4D93-A528-C4BC60837673Q37538782-F73C1617-89CF-439F-9592-010FB2F06812Q38829932-C475C434-3EC0-4418-BE96-68509E1AF9C2Q38919690-8A171508-0574-4672-842D-0DA7D46993F7Q38987096-94F74FA6-3D91-4075-A434-BDB36B46A679Q40040786-FD4D3C8B-72EE-4DD9-B8E4-00368BBC0E2AQ40045642-3F1C898C-B07C-4936-97A7-CD1C22980B0EQ40248126-BCC34B09-BDB3-4462-9FD9-8F2702F87A94Q41188300-57C104BB-845D-4E81-A369-F70935919F9BQ47098888-5B3C3449-4B63-4832-ABA8-FC8C5E3EBF81Q47151374-A56FA6F9-3C3E-4C5A-801E-E93321F3C758Q49167496-25D360A8-1DE3-44D9-A921-CB5D4381F2AFQ50094753-BC18F32E-99E4-4F7C-87CC-58D4BB902518
P2860
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model
@ast
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model
@en
type
label
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model
@ast
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model
@en
prefLabel
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model
@ast
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model
@en
P2860
P50
P921
P356
P1476
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model
@en
P2093
Roger J M Brüggemann
P2860
P304
P356
10.1128/AAC.04907-14
P407
P577
2015-03-09T00:00:00Z